Brinker Capital Investments’s Teva Pharmaceuticals TEVA Stock Holding History

Brinker Capital Investments’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$730K	Buy	21,552 +4,277	+25%	+$142K	0.01%	1323
2026 Q1	$520K	Buy	17,275 +241	+1%	+$7.75K	﹤0.01%	1435
2025 Q4	$532K	Buy	17,034 +5,089	+43%	+$125K	﹤0.01%	1573
2025 Q3	$241K	Sell	11,945 -529	-4%	-$9.29K	﹤0.01%	1880
2025 Q2	$209K	Buy	12,474 +2,341	+23%	+$37.8K	﹤0.01%	1870
2025 Q1	$156K	Sell	10,133 -2,169	-18%	-$38.7K	﹤0.01%	1830
2024 Q4	$271K	Buy	12,302 +1,310	+12%	+$23.8K	﹤0.01%	1603
2024 Q3	$198K	Buy	+10,992	New	+$192K	﹤0.01%	1718
2016 Q4	–	Sell	-80	Closed	-$4K	–	638
2016 Q3	$4K	Buy	+80	New	+$4.17K	﹤0.01%	427
2015 Q1	–	Sell	-200	Closed	-$12K	–	469
2014 Q4	$12K	Hold	200	–	–	﹤0.01%	356
2014 Q3	$11K	Hold	200	–	–	﹤0.01%	327
2014 Q2	$10K	Hold	200	–	–	﹤0.01%	331
2014 Q1	$11K	Hold	200	–	–	﹤0.01%	348
2013 Q4	$8K	Hold	200	–	–	﹤0.01%	334
2013 Q3	$8K	Hold	200	–	–	﹤0.01%	335
2013 Q2	$8K	Buy	+200	New	+$7.79K	﹤0.01%	322

Other funds holding TEVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Brinker Capital Investments's TEVA Position: Q2 2026 in Review

Brinker Capital Investments increased its Teva Pharmaceuticals (TEVA) stake by 25% in Q2 2026, buying an estimated $142K and bringing the position to 21,552 shares worth $730K. The position accounts for 0.01% of the portfolio, ranked #1323.

Brinker Capital Investments first reported a position in TEVA in Q2 2013 and has held it in 16 quarters since. 673 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

Brinker Capital Investments held 21,552 shares of Teva Pharmaceuticals worth $730K as of Q2 2026.
Brinker Capital Investments bought 4,277 Teva Pharmaceuticals shares in Q2 2026, an estimated $142K.
Teva Pharmaceuticals made up 0.01% of Brinker Capital Investments's portfolio in Q2 2026, its #1323 holding.
Brinker Capital Investments first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 16 quarters since.
673 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Brinker Capital Investments's 13F filing for Q2 2026, filed 14 Aug 2026.